Slay Sarcoma Research Initiative (SSRI)
Slay Sarcoma Research Initiative was incorporated December 31st, 2015 and became a non-profit 501(c)3 approved organization on June 6th, 2016.
The sole mission of the SSRI Inc. is to find a cure for leiomyosarcoma. This will be accomplished by promoting awareness, fund-raising for scientific grant award distribution, and donations to organizations and individuals to this end.
Leiomyosarcoma remains a difficult disease to treat despite the use of modalities such as chemotherapy and radiation. Knowledge gaps exist in areas concerning the etiology, progression and treatment of LMS. New biologic medications that target specific components of the immune system are recent discoveries that may prove to be useful in this disease. Combination of modalities may ultimately be needed in combating LMS, although specific agents, dosing and sequence of interventions need to be determined.